Artera Receives FDA Clearance for AI Breast Cancer Risk Stratification Tool
Tags AI · Health Tech
Artera received FDA clearance for ArteraAI Breast, the first digital pathology-based risk stratification tool for early-stage HR+/HER2- invasive breast cancer. The tool generates an AI-derived risk score for distant metastasis using digitized histopathology images and clinical variables. It follows Artera's earlier FDA De Novo authorization for its AI prostate cancer tool and recent CE marking for both assays. The clearance follows data presented at the 2025 San Antonio Breast Cancer Symposium.
Technical significance
ArteraAI Breast addresses a genuine clinical need: determining which early-stage breast cancer patients will benefit from chemotherapy. Current clinical-pathological factors leave significant uncertainty, leading to both over- and under-treatment. The company's expanding regulatory footprint (US FDA + EU CE mark for both prostate and breast) positions it as a leader in AI-based cancer diagnostics.